

10/825,610C>

05/28/2007

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:03:31 ON 28 MAY 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:03:48 ON 28 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAY 2007 HIGHEST RN 935984-33-1

DICTIONARY FILE UPDATES: 27 MAY 2007 HIGHEST RN 935984-33-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10825610.str



chain nodes :

12 13 14 15 16 17 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

6-7 9-12 10-17 12-13 13-14 13-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

8-9 9-10 9-12 10-17 12-13 13-14 13-15 14-16

exact bonds :

6-7 7-8 7-11 10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS


21:CLASS 22:Atom 23:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:04:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*


PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\108256101.str



chain nodes :

12 13 14 15 16 17 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

6-7 9-12 10-17 12-13 13-14 13-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

8-9 9-10 9-12 10-17 13-14 13-15 14-16

exact bonds :

6-7 7-8 7-11 10-11 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS


21:CLASS 22:Atom 23:Atom

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 18:05:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 61 TO ITERATE

100.0% PROCESSED 61 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 752 TO 1688

PROJECTED ANSWERS: 68 TO 532


L4 15 SEA SSS SAM L3

=>

Uploading C:\Program Files\Stnexp\Queries\108256102.str

10/825,610C>

05/28/2007



chain nodes :

12 13 14 15 16 17 20 21 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

6-7 9-12 10-17 12-13 13-14 13-15 14-16 20-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

8-9 9-10 9-12 10-17 13-14 13-15 14-16 20-25

exact bonds :

6-7 7-8 7-11 10-11 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS


21:CLASS 22:Atom 23:Atom 25:Atom

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 18:06:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 61 TO ITERATE

100.0% PROCESSED 61 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 752 TO 1688

PROJECTED ANSWERS: 9 TO 360

L6 9 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 18:07:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1283 TO ITERATE

100.0% PROCESSED 1283 ITERATIONS

100 ANSWERS

SEARCH TIME: 00.00.01

L7 100 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

174.35

174.56

FILE 'CAPLUS' ENTERED AT 18:07:12 ON 28 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 May 2007 VOL 146 ISS 23  
FILE LAST UPDATED: 27 May 2007 (20070527/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l7

L8                    3 L7

=> d ibib abs hitstr tot


10/825,610C&gt;

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2006:381237 CAPLUS  
 DOCUMENT NUMBER: 144:432794  
 TITLE: Preparation of 4-(substituted-phenyl)-2-pyrrolidinone derivatives as selective phosphodiesterase 4 inhibitors  
 INVENTOR(S): Hopper, Allen T.; Dunn, Robert Francis; Kuester, Erik, Mikal; Conticello, Richard Dennis; Liu, Ruiping; Tehim, Ashok  
 PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 199 pp.  
 CODEN: PIXKD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044955	A1	20060427	WO 2005-US37568	20051020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LA, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KM, KZ, MD, RU, TJ, TM				
US 2006135535	A1	20060622	US 2005-253812	20051020
PRIORITY APPL. INFO.:			US 2004-619964P	P 20041020
OTHER SOURCE(S):	MARPAT 144:432794			
GI				

05/28/2007

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title pyrrolidinones compds. I [R<sub>1</sub> = alkyl, wherein optionally 1 or more CH<sub>2</sub>CH<sub>2</sub> groups are replaced by CH:CH or C≡C bond, C, (un)substituted cycloalkyl, aryl, arylalkyl, aryl-alkenyl, (un)saturated heterocyclyl, heterocyclyl-alkyl, etc.; R<sub>2</sub> = (un)substituted alkyl; R<sub>3</sub> = C(=O)R<sub>4</sub>; CH<sub>2</sub>CO<sub>2</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>n</sub>SR<sub>5</sub>, etc.; R<sub>4</sub> = (un)substituted alkoxyalkyl, cycloalkyl, aryl, arylalkyl, etc.; R<sub>5</sub> = H, (un)substituted alkoxyalkyl, cycloalkyl, aryl, etc.], were prepared. The invention compds. exhibited improved phosphodiesterase 4 (PDE4) inhibition as compared to compds. such as rolipram and showed selectivity with regard to inhibition of other classes of PDEs. Selected I blocked the human PDE4 mediated conversion of cAMP to adenosine with IC<sub>50</sub> values < 10 nM. Thus, I and their pharmaceutical compns. are useful for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease (no data). Thus,

(4S)-1-[N-(4-ethoxycarbonyl-thiazol-2-yl)aminocarbonylmethyl]-4-[4-methoxy-3-(3R)-tetrahydrofuran-2-yl]oxyphenyl]-2-pyrrolidinone was prepared and tested in vitro and in rats as phosphodiesterase 4 inhibitor.

IT 790297-42-6P 790297-85-7P 790298-05-4P  
 790298-30-5P 790298-89-4P 790298-90-7P  
 790298-91-8P 790298-92-9P 790298-93-0P  
 790298-94-1P 790298-95-2P 885054-95-5P  
 885054-96-6P 885054-98-8P 885054-99-9P  
 885055-01-6P 885055-02-7P 885055-03-8P  
 885055-04-9P 885055-05-0P 885055-41-4P  
 885055-42-5P 885055-43-6P 885055-44-7P  
 885055-45-8P 885055-46-9P 885055-47-0P  
 885055-48-1P 885055-49-2P 885055-50-5P  
 885055-51-6P 885055-52-7P 885055-53-8P

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

885055-54-9P 885055-55-0P 885055-56-1P  
 885055-57-2P 885055-58-3P 885055-59-4P  
 885055-60-7P 885055-61-8P 885055-62-9P  
 885055-63-0P 885055-64-1P 885055-67-4P  
 885055-68-5P 885055-69-6P 885055-91-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of 4-(substituted-phenyl)-2-pyrrolidinone derivs. as selective phosphodiesterase 4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

RN 790297-42-6 CAPLUS

CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-(4-methyl-2-benzothiazolyl)-2-oxo-, (4S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 790297-85-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(4S)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-, ethyl ester (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 790298-05-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(4S)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 790298-30-5 CAPLUS

CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-N-[5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-69-4 CAPLUS

CN 1-Pyrrolidineacetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-, (4S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 790298-90-7 CAPLUS

CN 1-Pyrrolidineacetamide, N-[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-, (4S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.

SAEED




RN 790298-91-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-[4-methoxyphenoxy]methyl]-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-92-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-[2-(4-morpholinyl)-2-oxoethyl]-1,3,4-thiadiazol-2-yl]-2-oxo-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 790298-93-0 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[5-[2-oxo-2-(1-piperidinyl)ethyl]-1,3,4-thiadiazol-2-yl]-, (4S)-(9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
furanyl]oxy]phenyl]-N-methyl-N-(3-methyl-5-isothiazolyl)-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885054-96-6 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-N-(4-methyl-2-thiazolyl)-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885054-98-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-N-[5-(4-pyridinyl)-1,3,4-thiadiazol-2-yl]-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885054-99-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-2-oxo-, (4S)-(9CI) (CA INDEX NAME)




RN 790298-94-1 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[5-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,3,4-thiadiazol-2-yl]-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-95-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[5-[[[(4S)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-1,3,4-thiadiazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885054-95-5 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
Absolute stereochemistry.




RN 885055-01-6 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-N-[3-methyl-1-(phenylmethyl)-1H-pyrazol-5-yl]-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-02-7 CAPLUS  
CN 1-Pyrrolidineacetamide, N-ethyl-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(4-methyl-2-thiazolyl)-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-03-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(cyclopropylmethyl)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(4-methyl-2-thiazolyl)-2-oxo-, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,610C&gt;

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 885055-04-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(cyclopropylmethyl)-4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-[3-(1-methylethyl)-1,2,4-thiadiazol-5-yl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-05-0 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(cyclopropylmethyl)-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-41-4 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 885055-44-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-45-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-46-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-47-0 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

SAEED

05/28/2007


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.




RN 885055-42-5 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-(2-furanyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-43-6 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-2-oxo-N-[5-(2-(1-piperidinyl)ethyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.




RN 885055-48-1 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-3-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-49-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-3-isoxazolyl-4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-50-5 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-((3R)-tetrahydro-3-furanyl)oxy]phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,610C&gt;

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 885055-51-6 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-N-[4-(phenylsulfonyl)-3-thienyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-52-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-N-1H-pyrazol-3-yl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885055-53-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-N-5-methyl-1,3,4-thiadiazol-2-yl-, (4S)- (9CI)


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 885055-57-2 CAPLUS  
CN 4-Isoxazolecarboxamide, 5-[[[4S]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-3-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-58-3 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-(3-methyl-5-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-59-4 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-(5-methyl-3-phenyl-4-isoxazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

SAEED

05/28/2007


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 885055-54-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-55-0 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885055-56-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(3-ethyl-1,2,4-thiadiazol-5-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 885055-60-7 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(3,5-dimethyl-4-isoxazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-61-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxyphenyl]-2-oxo-N-pyrazinyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/825,610C&gt;

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 885055-62-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(1-ethyl-1H-pyrazol-5-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-63-0 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[3-(phenylamino)-1,2,4-thiadiazol-5-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885055-64-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[3-(phenylamino)-1,2,4-thiadiazol-5-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 885055-91-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(4-cyclopropyl-2-thiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


05/28/2007

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 885055-67-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(4-cyano-2-thienyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-68-5 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(2-thienyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885055-69-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(trifluoromethyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:927168 CAPLUS  
 DOCUMENT NUMBER: 141:395413  
 TITLE: Preparation of 4-(substituted-phenyl)-2-pyrrolidinone derivatives as selective phosphodiesterase 4 inhibitors  
 INVENTOR(S): Tehim, Ashok; Hopper, Allen; Liu, Ruiping; Kuester, Erik; Dunn, Robert F.; Renau, Thomas E.  
 PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA; Hoffmann La-Roche Inc.  
 SOURCE: PCT Int. Appl., 195 pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094375	A2	20041104	WO 2004-US11765	20040416
WO 2004094375	A3	20050421		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004232958	A1	20041104	AU 2004-232958	20040416
CA 2522631	A1	20041104	CA 2004-2522631	20040416
US 2005026913	A1	20050203	US 2004-825610	20040416
EP 1613590	A2	20060111	EP 2004-750220	20040416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,			
HR	BR 2004010235	A	20060509	BR 2004-10235
CN 1805929	A	20060719	CN 2004-80016778	20040416
JP 2006523710	T	20061019	JP 2006-510117	20040416
PRIORITY APPLN. INFO.:			US 2003-463054P	P 20030416
			WO 2004-US11765	W 20040416

OTHER SOURCE(S): MARPAT 141:395413  
 GI

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



I



II

AB Title pyrrolidinones compds. I [R1 = alkyl, wherein optionally 1 or more CH2CH2 groups are replaced by CH:CH or C≡C bond, C, (un)substituted cycloalkyl, aryl, arylalkyl, arylalkenyl, (un)saturated heterocyclyl, heterocyclylalkyl, etc.; R2 = (un)substituted alkyl; R3 = C(=O)R4; CH2CO2R5, (CH2)nSR5, etc.; R4 = (un)substituted alkoxyalkyl, cycloalkyl, aryl, arylalkyl, etc.; R5 = H, (un)substituted alkoxyalkyl, cycloalkyl, aryl, etc.] were prepared. The invention compds. exhibited improved phosphodiesterase 4 (PDE4) inhibition as compared to compds. such as rolipram and showed selectivity with regard to inhibition of other classes

of PDEs. For example, reacting 4-(3-cyclopentylthio-4-methoxyphenyl)-2-pyrrolidinone with 2,3-difluorobenzyl bromide gave II in 70% yield. Selected I blocked the human PDE4 mediated conversion of cAMP to adenosine

with IC50 values < 10 nM. Thus, I and their pharmaceutical compns. are useful for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease (no data).

IT 790297-85-7P, (4S)-1-[[[N-(4-ethoxycarbonylthiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(PDE4 inhibitor; preparation of phenylpyrrolidinones as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)

RN 790297-85-7 CAPLUS

CN 4-(thiazolecarboxylic acid, 2-)-[[[4S]-4-[4-methoxy-3-((3R)-tetrahydro-3-

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-74-4P, (4S)-1-[[[N-(indol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-76-6P, (4S)-1-[[[N-(5-chlorothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-77-7P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-phenylthiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-78-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(6-methoxybenzothiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-79-9P, (4S)-1-[[[N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-84-6P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(benzothiazol-6-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-86-8P, (4S)-1-[[[N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-88-0P, (4S)-1-[[[N-(cyclopropylmethyl-N-(6-fluorobenzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-93-7P,

(4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(2,2,3,3-tetrafluorobenzol-1,4-dioxan-6-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-94-8P 790297-96-0P, (4S)-1-[[[N-(1,4-benzodioxan-6-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-02-1P, (4S)-1-[[[N-(4-(4-fluorophenyl)thiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-04-3P, (4S)-1-[[[N-(4,6-difluorobenzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-05-4P, (4S)-1-[[[N-(4-carboxythiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-15-6P, (4S)-1-[[[N-(5-cyclopropylmethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-17-8P, (4S)-1-[[[N-(6-ethylpyridin-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-24-7P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-25-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(4-pyridinyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-25-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-(3-pyridinyl)thiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-27-0P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-


yloxy)phenyl]-1-[[[N-(4-(2-pyridinyl)thiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-29-2P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-(4-pyridinyl)thiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-30-5P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-56-5P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-

yloxy)phenyl]-1-[[[N-(6-methylpyridin-2-yl)-N-methylamino]carbonyl]methyl]-2-pyrrolidinone 790298-57-6P, (4S)-1-[[[N-(4,5-dimethylthiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-67-8P, (4S)-4-[4-methoxy-3-

SAEED

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
furanlyloxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-, ethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 514215-59-9P, (4S)-[4-Methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(6-methylpyridin-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 514216-32-1P, 1-[[[N-(6-bromopyridin-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-42-6P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-methylbenzothiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-43-7P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-methylthiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-44-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(6-methylbenzothiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-45-9P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-methoxybenzothiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-46-0P, (4S)-1-[[[N-(6-ethoxycarbonylbenzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-47-1P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(6-trifluoromethoxybenzothiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-48-2P, (4S)-1-[[[N-(4-tert-butylthiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-59-5P, (4S)-1-[[[N-(6-fluorobenzothiazol-2-yl)-N-methylamino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-68-6P, (4S)-1-[[[N-(3,4-methylenedioxyphenyl)-N-methylamino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-69-7P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-methylthiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-71-1P, (4S)-1-[[[N-(6-chlorobenzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790297-72-2P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-methyl-N-(thiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790297-73-3P, (4S)-1-[[[N-(Benzothiazol-2-yl)-N-(cyclopropylmethyl)amino]carbonyl]methyl

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


(3R)-tetrahydrofuran-3-yloxy]phenyl]-1-[[[N-(2-thiazolyl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-71-4P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(3,4-methylenedioxyphenyl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-72-5P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(4-trifluoromethylpyridin-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-75-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-chlorobenzoxazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-76-9P, (4S)-1-[[[N-(Benzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-77-0P, (4S)-1-[[[N-(6-fluorobenzothiazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-78-1P, (4S)-1-[[[N-(Benzimidazol-2-yl)amino]carbonyl]methyl]-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-2-pyrrolidinone 790298-79-2P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-80-5P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-methoxycarbonyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-81-6P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(3,4-methylenedioxyphenyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-83-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(2-thienyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-84-9P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(2-thienylmethyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-85-0P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(propan-2-yl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-86-1P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(2-pyrazinyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-87-2P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-88-3P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(tetrahydrofuran-2-yl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-89-4P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-

yloxy)phenyl]-1-[[[N-(5-aminosulfonyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-90-7P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-91-8P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-((4-methoxyphenyl)oxy)methyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-92-9P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-((4-morpholinyl)carbonyl]methyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-93-0P, (4S)-4-[4-methoxy-3-((3R)-tetrahydrofuran-3-yloxy)phenyl]-1-[[[N-(5-(1-piperidinyl)carbonyl]methyl)-1,3,4-thiadiazol-2-yl)amino]carbonyl]methyl]-2-pyrrolidinone 790298-94-1P, (4S)-4-[4-methoxy-3-((3R)-

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

pyrrolidinyl)carbonylmethyl]-1,3,4-thiadiazol-2-yl]amino]carbonylmethyl]-2-pyrrolidinone 790298-95-2P  
 RL: PAC (Pharmacological activity); SFN (Synthetic preparation); THW (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (PDE4 inhibitor; prepn. of phenylpyrrolidinones as selective PDE4 inhibitors for enhancing cognition and treating psychosis, allergic conditions, or inflammatory disease)  
 RN 514215-59-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(6-methyl-2-pyridinyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 514216-32-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(6-bromo-2-pyridinyl)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 790297-42-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(4-methyl-2-benzothiazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 790297-43-7 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(5-methyl-2-thiazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790297-44-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(6-methyl-2-benzothiazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-45-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(4-methoxy-2-benzothiazolyl)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 790297-46-0 CAPLUS  
 CN 6-Benzothiazolecarboxylic acid, 2-[[[(4S)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790297-47-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[6-(trifluoromethoxy)-2-benzothiazolyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-48-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[4-[[1,1-dimethylethyl]-2-thiazolyl]-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-59-5 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-(6-fluoro-2-benzothiazolyl)-4-[4-methoxy-3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,610C&gt;

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790297-68-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-1,3-benzodioxol-5-yl-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-69-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(4-methyl-2-thiazolyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-71-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(6-chloro-2-benzothiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 790297-74-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-1H-indol-2-yl-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-76-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(5-chloro-2-thiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-77-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-(4-phenyl-2-thiazolyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-78-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(6-methoxy-2-benzothiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

SAEED

05/28/2007


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 790297-72-2 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-2-oxo-N-2-thiazolyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-73-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-2-benzothiazolyl-N-(cyclopropylmethyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 790297-83-5 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-84-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-6-benzothiazolyl-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-86-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,610C&gt;

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790297-88-0 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(cyclopropylmethyl)-N-(6-fluoro-2-benzothiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-93-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790297-94-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(2,2-difluoro-1,3-benzodioxol-5-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790298-04-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(4,6-difluoro-2-benzothiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-05-4 CAPLUS  
CN 4-Thiazolecarboxylic acid, 2-[[[4S]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-15-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-(cyclopropylmethyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

SAEED

05/28/2007


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
3-[[[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790297-96-0 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 790298-02-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(4-(4-fluorophenyl)-2-thiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790298-17-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(6-ethyl-2-pyridinyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-24-7 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-25-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[5-(4-pyridinyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)


10/825,610C&gt;

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 790298-26-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(3-pyridinyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 790298-26-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(3-pyridinyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 790298-27-0 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(2-pyridinyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 790298-57-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(4,5-dimethyl-2-thiazolyl)-4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 790298-67-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-2-thiazolyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 790298-71-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-1,3-benzodioxol-5-yl-4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

SAEED


05/28/2007

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 790298-29-2 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(4-pyridinyl)-2-thiazolyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 790298-30-5 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[5-(4-piperidinyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 790298-56-5 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-N-methyl-N-(6-methyl-2-pyridinyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 790298-72-5 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-N-[4-(trifluoromethyl)-2-pyridinyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 790298-75-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-(5-chloro-2-benzoxazolyl)-4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 790298-76-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-2-benzothiazolyl-4-[4-methoxy-3-[[[3R]-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

10/825,610C&gt;


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 790298-77-0 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(6-fluoro-2-benzothiazolyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-78-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-1H-benzimidazol-2-yl-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-79-2 CAPLUS  
CN 1,3,4-Thiadiazole-2-carboxylic acid, 5-[[[(4S)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 790298-84-9 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-(2-thienylmethyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-85-0 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-86-1 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


05/28/2007

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790298-80-5 CAPLUS  
CN 1,3,4-Thiadiazole-2-carboxylic acid, 5-[[[(4S)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-1-pyrrolidinyl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-81-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-(1,3-benzodioxol-5-yl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790298-83-8 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-(2-thienyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 790298-87-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 790298-88-3 CAPLUS  
CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-[5-(tetrahydro-2-furanyl)-1,3,4-thiadiazol-2-yl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 790298-89-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/825,610C&gt;

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [X = O; R1 = alkyl, cycloalkyl, heterocyclic, etc.; R2 = alkyl; R3 = H, alkyl, cycloalkyl, arylalkyl, etc.] are prepared for instance, Me 3-(3-benzyloxy-4-methoxyphenyl)-4-nitrobutanoate is converted

to 3-benzyloxy-4-methoxyphenyl (MeOH, NiCl<sub>2</sub>, NaBH<sub>4</sub>, 30 min, 0°) and subsequently debenzylated (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, H<sub>2</sub>-10% Pd/C, 20 psi, 8 h). This intermediate is then coupled to 4-chlorophenylboronic acid (CH<sub>2</sub>Cl<sub>2</sub>, Cu(OAc)<sub>2</sub>, Et<sub>3</sub>N, 18 h) to give II. I exhibit improved PDE4 inhibition as compared to rolipram and show selectivity with regard to inhibition of other classes of PDEs.

IT 514215-59-9P 514216-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidinone deriva.

as PDE-4 inhibitors for treatment of neurol. syndromes)


RN 514215-59-9 CAPLUS

CN 1-Pyrrolidineacetamide, 4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-N-(6-methyl-2-pyridinyl)-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

05/28/2007


L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 514216-32-1 CAPLUS

CN 1-Pyrrolidineacetamide, N-(6-bromo-2-pyridinyl)-4-[4-methoxy-3-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10/825,610C>

05/28/2007

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.22

191.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

STN INTERNATIONAL LOGOFF AT 18:09:02 ON 28 MAY 2007